HUMA Stock Overview
Engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Humacyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.56 |
| 52 Week High | US$7.78 |
| 52 Week Low | US$1.96 |
| Beta | 1.27 |
| 1 Month Change | 104.32% |
| 3 Month Change | 75.61% |
| 1 Year Change | 92.86% |
| 3 Year Change | -23.79% |
| 5 Year Change | n/a |
| Change since IPO | -21.82% |
Recent News & Updates
Shareholder Returns
| HUMA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 16.8% | 0.7% | 1.2% |
| 1Y | 92.9% | 5.0% | 27.7% |
Return vs Industry: HUMA exceeded the US Biotechs industry which returned 5% over the past year.
Return vs Market: HUMA exceeded the US Market which returned 27.7% over the past year.
Price Volatility
| HUMA volatility | |
|---|---|
| HUMA Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: HUMA's share price has been volatile over the past 3 months.
Volatility Over Time: HUMA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 184 | Laura Niklason | www.humacyte.com |
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.
Humacyte, Inc. Fundamentals Summary
| HUMA fundamental statistics | |
|---|---|
| Market cap | US$837.16m |
| Earnings (TTM) | -US$105.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.5x
P/E RatioIs HUMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HUMA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$5.70m |
| Gross Profit | -US$5.70m |
| Other Expenses | US$100.00m |
| Earnings | -US$105.70m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.89 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did HUMA perform over the long term?
See historical performance and comparison